The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Colorectal cancer highlights at ESMO 2024: CheckMate 8HW and BREAKWATER
Dominik Modest, MD, Charité – Universitätsmedizin Berlin, Berlin, Germany, gives his highlights in colorectal cancer presented at the European Society for Medical Oncology (ESMO) 2024 Congress, including the outcomes from the CheckMate 8HW study (NCT04008030), which compared first-line nivolumab with ipilimumab to chemotherapy in MSI-H/dMMR metastatic colorectal cancer (mCRC). Dr Modest additionally comments on updates in KRAS G12C colorectal cancer and the BREAKWATER trial (NCT04607421). This interview took place at the ESMO 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
